Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 20 January

Paulina Peters
January 20, 2022

Morning Bell 19 January

Sophia Mavridis
January 19, 2022

Morning Bell 18 January

Paulina Peters
January 18, 2022

Morning Bell 17 January

Sophia Mavridis
January 17, 2022

Weekly Wrap 14 January

Sophia Mavridis
January 14, 2022

Morning Bell 13 January

Paulina Peters
January 13, 2022

Morning Bell 12 January

Sophia Mavridis
January 12, 2022

Morning Bell 11 January

Paulina Peters
January 11, 2022

Morning Bell 10 January

Sophia Mavridis
January 10, 2022

Thank you & see you in 2022

Sophia Mavridis
December 21, 2021

Morning Bell 17 December

Sophia Mavridis
December 17, 2021

Morning Bell 16 December

Paulina Peters
December 16, 2021